October 01, 2014 6:21 PM ET

Pharmaceuticals

Company Overview of Mersana Therapeutics, Inc.

Company Overview

Mersana Therapeutics, Inc., a biopharmaceutical company, engineers drug conjugates that maximize the potential of new and established therapeutic classes. The company develops a portfolio of antibody-drug conjugates to improve patient outcomes in multiple oncology indications. Its clinical-stage product candidates include XMT-1001, a “tecan” conjugate for patients with lung cancers; and XMT-1107, an anti-angiogenic conjugate for patients with refractory, advanced solid tumors. The company’s conjugation system provides benefits for the development of drugs across therapeutic modalities, including antibody-drug conjugates, antibody fragments, small molecules, biologics, and synergistic drug co...

840 Memorial Drive

Cambridge, MA 02139

United States

Founded in 2001

Phone:

617-498-0020

Fax:

617-498-0109

Key Executives for Mersana Therapeutics, Inc.

Executive Chairman
Age: 49
Co-Founder
Vice President of Finance
Head of Clinical Development & Regulatory Affairs
Age: 59
Chief Medical Officer
Compensation as of Fiscal Year 2014.

Mersana Therapeutics, Inc. Key Developments

Merck and Mersana Collaborate to Develop Antibody-Drug Conjugates for Cancer

Merck Serono and Mersana Therapeutics, Inc. have collaborated to develop next-generation antibody-drug conjugates, or ADCs, for cancer. ADCs are composed of an antibody linked to cytotoxic drugs, whereby the antibody part specifically targets and delivers the cytotoxic drug to cancer cells which could lead to higher drug levels at the tumor site. Mersana and Merck Serono will leverage Mersana's Fleximer technology to generate ADCs for multiple undisclosed targets. Both parties have agreed to test a variety of ADCs by utilizing Mersana's platform technologies and several cytotoxic agents as conjugates. This agreement further underlines Merck Serono's approach to employ a collaborative R&D model, creating strategic partnerships to drive innovation, being consciously agnostic of the source of potential novel assets, and technologies.

Mersana Therapeutics, Inc. and Merck KGaA Announce an Agreement to Develop Next-Generation Antibody-Drug Conjugates

Mersana Therapeutics, Inc. and the biopharmaceutical division of Merck KGaA announced an agreement to collaboratively develop next-generation antibody-drug conjugates (ADCs). ADCs are composed of an antibody linked to cytotoxic drugs, whereby the antibody specifically targets and delivers the cytotoxic drug to cancer cells, which could lead to higher drug levels at the tumor site. Mersana and the biopharmaceutical division of Merck KGaA will leverage Mersana's Fleximer(R) technology to generate ADCs for multiple undisclosed targets. Both parties have agreed to test a variety of ADCs by utilizing Mersana's platform technologies and several cytotoxic agents as conjugates. Under the agreement, Merck KGaA will provide monoclonal antibodies to Mersana, which will generate the Fleximer-ADCs and conduct drug discovery and preclinical development activities. Merck KGaA will be responsible for clinical development and commercialization of any products under an exclusive license from Mersana. In addition to an upfront payment, Mersana is eligible to receive milestones plus royalties on worldwide net sales of products.

Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates

Mersana Therapeutics, Inc. announced that it has entered into a collaboration agreement with Millennium Pharmaceuticals, Inc. to develop next-generation, Fleximer(R) antibody-drug conjugates (ADCs). Mersana's proprietary conjugation technology is comprised of the company's biodegradable Fleximer polymer and a broad array of customizable linker chemistries matched to Mersana's diverse, cytotoxic payloads. Under the agreement, Takeda will provide an upfront payment to Mersana for the right to utilize Fleximer technology to develop novel ADC candidates. Mersana is responsible for conducting research and creating ADCs that are conjugates of Takeda's antibodies and Mersana's diverse payload platforms, which combine a cytotoxic payload with the Fleximer polymer and custom linkers. In addition to providing antibodies, Takeda is responsible for product development, manufacturing and commercialization of any Fleximer-ADC products. In addition to an upfront payment, Mersana is eligible to receive milestones and royalties on worldwide net sales of any resulting ADC products.

Similar Private Companies By Industry

Company Name Region
Symphony Icon, Inc. United States
Pharmanex, LLC United States
AmeReGen BioPharmaceuticals Inc. United States
Santarus, Inc. United States
Angiogen LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Mersana Therapeutics, Inc., please visit www.mersana.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.